Allergan (AGN - option chain) shares are rising today after the company announced FDA approval of Allergan's Botox for use as a treatment for chronic Migraine headaches on Friday after the close of trading. This opens an entirely new market for that drug, which was almost exclusively used for cosmetic purposes. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AGN.

AGN opened this morning at $71.97. So far today the stock has hit a low of $71.14 and a high of $72.56. As of 12:10, AGN is trading at $72.43 up $3.57 (5.2%). The chart for AGN looks bullish and S&P gives AGN a positive 4 STARS (out of 5) buy ranking.

As the opening bell sounded and stocks got off to a sluggish start, I decided to take a look for stocks that got off to a fast start. One of those stocks is Botox-maker Allergan (AGN). In early trading, the pharmaceutical firm was more than a percentage point higher, so I took to digging to find out why.

The biggest news I found for Allergan was that it entered into an Amended and Restated License, Development and Marketing Agreement with Inspire Pharmaceuticals. The agreement deals with terms related to the Prolacria 2% development program and Inspire's right to receive revenues from Allergan relating to net sales of Restasis and any other human opthalmic formulations of cyclosporine owned or controlled by Allergan. Simply put, Inspire will receive revenues on net sales of Restasis and any related cyclosporine-based medicines.

Drug manufacturer Allergan, Inc. (AGN) will be reporting its second quarter results on Monday, with analysts expecting to see an 8% earnings increase from the same period last year.

Analysts have forecast earnings of $0.81 for the quarter, versus $0.75 during the same period last year.

Allergan has managed to outpace analyst estimates for each of the past six quarters, and has not failed to at least match estimates since the first quarter of 2007.

Analyst upgrades:

• Morgan Keegan upgraded Copano Energy (CPNO) to Outperform from Market Perform based on the $300M capital infusion it received from TPG Capital.
• Wells Fargo upgraded SunTrust (STI) to Market Perform from Underperform following the company's Q2 results citing improving credit quality trends and valuation.
• UBS upgraded Baidu (BIDU) to Buy from Neutral based on solid fundamentals following the strong Q2 report and guidance and valuation. The firm raised its price target to $92 from $69.
• Baxter (BAX) was upgraded to Conviction Buy from Neutral at Goldman.
• JetBlue (JBLU) was upgraded to Buy from Hold at Soleil.
• Penn Virginia GP (PVG) was upgraded to Outperform from Sector Perform at RBC Capital.

Analyst downgrades:

• Piper Jaffray downgraded Beckman Coulter (BEC) to Neutral from Overweight following the company's weaker than expected Q2 results and lowered guidance. The firm lowered its target for shares to $60 from $74. Shares were also downgraded to Hold from Buy at Jefferies and to Neutral from outperform at Baird following the company's reduced guidance.
• Keefe Bruyette cut AmeriCredit (ACF) to Market Perform from Outperform following the acquisition by General Motors (GM, MTLQQ).
• FBR Capital downgraded SunTrust (STI) to Market Perform from Outperform and lowered its price target to $27 from $34. The analyst believes larger banks are better positioned than regionals due to greater prospects of reserve releases.
• Travelers (TRV) was downgraded to Perform from Outperform at Oppenheimer.
• Lender Processing (LPS) was downgraded to Neutral from Buy at Goldman.
• Penn Virginia Resource (PVR) was downgraded to Sector Perform at RBC Capital.

Analyst initiations:

• ThinkEquity assumed coverage of SanDisk (SNDK) with a Buy rating.
• Macquarie initiated Allergan (AGN) with an Outperform rating and $75 price target.
• Macquarie also initiated Cooper Companies (COO) with an Outperform rating and $45 price target.
• NCR Corp (NCR) was initiated with a Hold rating at KeyBanc.
• CryoLife (CRY) was started at Benchmark Co. with a Buy rating and $8 target.
• China New Borun (BORN) was initiated with an Overweight rating and $7.40 target at Piper Jaffray.

If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).

Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan.

Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81.

It appears that U.S.-based drug makers and cigarette companies caught the attention of traders Tuesday -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot Friday:

Allergan (AGN - option chain) shares are rising today after the FDA approved Allergan's drug Botox for treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AGN.

AGN opened this morning at $62.60. So far today the stock has hit a low of $61.90 and a high of $62.78. As of 12:00, AGN is trading at $62.42 up $1.07 (1.7%). The chart for AGN looks neutral and S&P gives AGN a neutral 3 STARS (out of 5) hold ranking.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Aetna Inc. (NYSE: AET) reported better-than-expected Q3 earnings and revenue, sending shares higher.
• Allergan Inc. (NYSE: AGN) reported better-than-expected Q3 numbers, sending shares higher.
• Bare Escentuals Inc. (NASDAQ: BARE) Q3 profit easily topped analysts' estimates, and shares surged.
• Cabot Oil & Gas Corp. (NYSE: COG) received an upgrade following the release of its Q3 numbers.
• Estee Lauder Companies Inc. (NYSE: EL) reported strong Q1 results, sending shares higher.
• E*Trade Financial Corp. (NASDAQ: ETFC) reported a smaller-than-expected net loss for Q3.
• Goodyear Tire & Rubber Co. (NYSE: GT) Q3 earnings topped estimates and revenue was up sequentially.

One would expect generic U.S. drugmaker Mylan (NYSE: MYL) to benefit from all this talk about increased generic competitions, but revenue only increased 5.2 percent to $1.26 billion on an operational basis, beating analyst revenue estimates of $1.23 billion. Still, revenue in North America, where most pharmas have been hurting, rose 9.2 percent to $502.5 million, helped by new product launches and increased volume.

On an adjusted basis, Mylan posted better-than-expected third-quarter results on Thursday, reporting an earnings per share of 32 cents -- 5 cents higher than the average estimate of analysts polled by Thomson Reuters I/B/E/S. It seems that just like branded pharmas, Mylan benefited from cost cuts. Still, the world's No. 3 generic drugmaker raised its full-year outlook and said it believes it can continue its current momentum into 2010.

Analyst upgrades:

• Citigroup upgraded Allergan (NYSE: AGN) to Buy from Hold to reflect increased estimates for Botox and its belief Latisse guidance looks conservative. The firm raised its target on shares to $57 from $45.
  
• Jefferies upgraded Texas Instruments (TXN) to Hold from Underperform after channel checks indicated business is strengthening. Jefferies believes Texas Instruments' September quarter guidance will come in better than expected and raised its target on shares to 23 from $16.
  
• FBR Capital upgraded Peabody Energy (BTU) to Outperform from Market Perform to reflect "strong" long-term steel and steam demand trends from China and India. The firm raised its target on shares to $44 from $36.
  
• Elan Corp (ELN) was upgraded to Buy from Neutral at UBS.
  
• Affymetrix (AFFX) was upgraded to Equal Weight from Underweight at Morgan Stanley.
  
• ASML Holding (ASML) was upgraded to Buy from Neutral at BofA/Merrill.

Analyst upgrades:

• Jefferies upgraded MDS Inc. (NYSE: MDZ) to Buy from Hold on valuation as it believes shares are pricing in a "worst case" scenario at current levels. The firm keeps a $6.50 target on the stock.
  
• JP Morgan upgraded Continental (NYSE: CAL) to Overweight from Neutral on valuation as it believes the recent sell-off is overdone. The firm keeps a $13 price target on the stock.
• Thomas Weisel is positive on Allergan's (NYSE: AGN) diverse product portfolio, global infrastructure, vertical integration, and deep pipeline. The firm upgraded shares to Overweight from Market Weight and has a $54 target on the stock.
• NetLogic (NASDAQ: NETL) was upgraded to Buy from Neutral at Piper.
  
• Dover (NYSE: DOV) was raised to Buy from Neutral at Banc of America/Merrill.
  
• Map Pharmaceuticals (NASDAQ: MAPP) was upgraded at Argus to Hold from Sell.

As Jon Ogg reported, Allergan, Inc. (NYSE: AGN - option chain) rallied sharply on Tuesday amid rumors that GlaxoSmithKline (NYSE: GSK) was mulling a takeover bid. Speculative investors jumped all over the news, as option volume on AGN skyrocketed well beyond normal levels yesterday. Interestingly enough, it seems that some traders took advantage of the stock's surge to initiate new bearish positions.

Specifically, AGN on Tuesday saw 15,850 puts cross the tape, which represents about 14.5 times its average daily put trading volume. Meanwhile, 59,943 call contracts changed hands, marking 11.5 times the norm.

Today's lack of a rally came with little surprise. The massive gains yesterday were reminders of the panic buying seen in the past. Profit takers used the strength to unload on the new buyers who chased stocks yesterday.

Confusing housing data caused another brief hope because of an uptick, but that was following a downward revision. The Geithner-Bernanke testimony to Congress today did very little for the markets. Here were today's unofficial closing bell levels:

Dow 7,660.37 -115.49 (-1.49%)
S&P 500 806.37 -16.55 (-2.01%)
Nasdaq 1,518.70 -37.07 (-2.38%)

Top Analyst Upgrades & Downgrades

Analyst upgrades:

• Jefferies upgraded Abiomed (NASDAQ: ABMD) to Hold from Underperform on valuation as it believes concerns over the company's Impella heart pump are priced in at current levels. The firm lowered its target price to $7 from $8.
  
• Suntrust upgraded Somanetics (NASDAQ: SMTS) to Neutral from Reduce. The firm believes most of the risk is out of Somanetics shares and that the Q1 report could be a positive catalyst.
  
• Banc of America/Merrill upgraded shares of Telecom Italia (NYSE: TI) to Buy from Neutral on valuation and believes the company's revenue trends are improving.
• China Petroleum & Chemical (NYSE: SNP) was raised to Buy from Neutral at UBS.
• Hexcel (NYSE: HXL) and Johnson Controls (NYSE: JCI) were upgraded to Buy from Neutral at Goldman.

Merck (NYSE: MRK) is recently trading at $25.54 in pre-open trading, below its close of $26.46. MRK expects 2009 top-line growth will be offset by the effects of a volatile global economy. MRK December option implied volatility of 70 is above its 26-week average of 43 according to Track Data, suggesting larger price movement.

Allergan (NYSE: AGN) discovers and develops specialty pharmaceutical products. AGN closed at $36.20. AGN's Latisse (Bimatoprost for eyelash growth) PDUFA date is expected in mid-year 2009. AGN December option implied volatility is at 76, July is at 55; above its 26-week average of 50 according to Track Data, suggesting larger price movement.

Celgene (NASDAQ: CELG), a biopharmaceutical company, closed at $52.60. CELG's Revlimid's (non-Hodgkin's lymphoma treatment) incremental Phase 3 data on Revlimid in first line multiple myeloma is expected at the American Society of Hematology (ASH) meeting on December 6 to December 9. CELG December option implied volatility of 75 is above its 26-week average of 53 according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com